Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9730
-0.0170 (-1.72%)
At close: Aug 29, 2025, 4:00 PM
0.9654
-0.0076 (-0.78%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$462,100
Profits / Employee
-$1,101,310
Market Cap
189.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% |
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IVVD News
- 3 days ago - Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions - Seeking Alpha
- 5 days ago - Invivyd to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 11 days ago - Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 12 days ago - Invivyd Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) - GlobeNewsWire
- 18 days ago - Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 18 days ago - Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 - GlobeNewsWire